Treatment with ASI significantly improved the activity of human tumor necrosis factor-beta (TNF-beta) and the levels of IgA, IgG, and IgM, as well as the activity of natural killer (NK) cells in patients with lung cancer [204]. The gene discussed is LTA; the disease is lung carcinoma.